Comparison of glucose lowering effect of Metformin and acarbose in type 2 diabetes mellitus: A Meta-analysis

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Gu, Shuyan ^a   Shi, Jihao ^b   Tang, Zhiliu ^c   Sawhney, Monika ^d   Hu, Huimei ^a   Shi, Lizheng ^e   Fonseca, Vivian ^f   Dong, Hengjin ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c BRISTOL MYERS SQUIBB   (United States)

^d MARSHALL UNIVERSITY   (United States)

^e TULANE UNIVERSITY   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ANTIDIABETIC ACTIVITY; ARTICLE; DRUG EFFICACY; HEMOGLOBIN BLOOD LEVEL; HUMAN; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; BLOOD; DIABETES MELLITUS, TYPE 2; FEMALE; MALE;

ACARBOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN;

EID: 84930634996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126704     Document Type: Article

References (98)

1. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. The journal of the American Medical Association. 2013;310(9):948-59. doi: 10.1001/jama.2013. 168118 PMID: 24002281.
2. International Diabetes federation. About diabetesTypes of diabetes. Available: http://www.idf.org/about-diabetes (Accessed 2014 March 10).
3. Chinese Diabetes Society. Chinese guideline forType 2 diabetes prevention (2013). Chinese Journal of diabetes. 2014;22(8):2-42.
4. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes care. 2014;37 Suppl 1:S14-80. doi: 10.2337/dc13-S011 PMID: 23264422; PubMed Central PMCID: PMC3537269.
5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2009;32(1):193-203. doi: 10.2337/dc08-9025 PMID: 18945920; PubMed Central PMCID: PMC2606813.
6. Diabetes Prevention Program Research G. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes care. 2012;35(4):731-7. doi: 10.2337/dc11-1299 PMID: 22442396; PubMed Central PMCID: PMC3308305.
7. Ji L, Lu J, Weng J, Jia W, Tian H, Zhu D, et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. Journal of diabetes. 2015;7(2):166-73. doi: 10.1111/1753-0407. 12165 PMID: 24809622.
8. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Available: http://www.cochrane-handbook.org (Accessed 2013 February 11).
9. Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic metaanalysis. Clinical therapeutics. 2013;35(6):880-99. doi: 10.1016/j.clinthera.2013.03.020 PMID: 23602502.
10. Van de Laar F, Lucassen P, Akkermans R, Van de Lisdonk E, Rutten G, Van Weel C. Alpha-glucosidase inhibitors fortype 2 diabetes mellitus (Review). The Cochrane Library. 2009; (1:): 1-180.
11. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of clinical epidemiology. 1997;50(6):683-91. PMID: 9250266.
12. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: Indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2009.
13. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. British Medical Journal. 2003;326(7387):472. doi: 10.1136/bmj.326.7387.472 PMID: 12609941; PubMed Central PMCID: PMC150178.
14. Chen LL, Zheng J. Comparison of the effect of acarbose, metformin and glipizide on newly diagnosed young type 2 diabetic patients. Chinese Journal of Endocrinology and Metabolism. 2004;20(5):449-50.
15. Chou WZ. Clinical observation of type 2 diabetes treatment with acarbose. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2013;22(26):2877-8.
16. Hong F. The analysis of efficacy and medication of several drugs to treat Type 2 Diabetes. China Practical Medicine. 2011;6(19):172-3.
17. Tang Y, Chen FM. The analysis of efficacy and side effects of acarbose and metformin to treat Type 2 Diabetes. National medical frontiers of China. 2013;8(16):18.
18. Wang HB, Deng XC, Feng YT. Clinical observation of diabetes II treatment with acarbose and metformin. Modern hospital. 2005;5(12):42-3.
19. Yang HL. Observation of Clinical Effect on Acarbose to treat Type 2 Diabetes. Medical Recapitulate. 2009;15(20):3196-7.
20. Zhang MH. Treatment effect of metformin and acarbose in patients with type 2 diabetic insulin resistance. Jilin Medical Journal. 2011;32(18):3682-3.
21. Zhu ZL, Qiu XC, Zhu HP, Ding ZJ. Application of acarbose combined with metformin in treatment of newly diagnosed type 2 diabetes patients. Heilongjiang Medicine Journal. 2011;24(2):223-5.
22. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study G. Effect of initial combination therapy with sitagliptin, adipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes care. 2007;30(8):1979-87. doi: 10.2337/dc07-0627 PMID: 17485570.
23. Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebocontrolled study. Diabetes, obesity and metabolism. 2012;14(6):565-74. doi: 10.1111/j.1463-1326.2012. 01590.x PMID: 22356132.
24. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology. 2001;37(5):1344-50. PMID: 11300445.
25. Uehara MH, Kohlmann NE, Zanella MT, Ferreira SR. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes, obesity and metabolism. 2001;3(5):319-25. PMID: 11703421.
26. Wu GT, Han YQ, Wang JY, Li WJ, Gu Y, Shi Y. Effects of Metformin on Insulin Resistance in Type 2 Diabetes Mellitus Patients. Journal of tongji university (medical science). 2001;22(6):31-5.
27. Chiasson JL, Naditch L, Miglitol Canadian University Investigator G. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes care. 2001;24(6):989-94. PMID: 11375358.
28. Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2004;20(6):883-9. PMID: 15200747
29. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care. 2009;32(4):650-7. doi: 10.2337/dc08-1863 PMID: 19114612; PubMed Central PMCID: PMC2660449.
30. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes research and clinical practice. 2011;93(1):56-62. doi: 10.1016/j.diabres.2010.11.030 PMID: 21146883.
31. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obesity research. 1998;6(1):47-53. PMID: 9526970.
32. Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. American journal of hypertension. 2004;17(3):223-7. doi: 10.1016/j.amjhyper.2003.11.006 PMID: 15001195.
33. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes, obesity and metabolism. 2012;14(9):852-8. doi: 10.1111/j.1463-1326.2012.01611.x PMID: 22519919.
34. Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 2002;51(12):3479-85. PMID: 12453903
35. Hallsten K, Virtanen KA, Lonnqvist F, Janatuinen T, Turiceanu M, Ronnemaa T, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabetic medicine: a journal of the British Diabetic Association. 2004;21(12):1280-7. doi: 10. 1111/j.1464-5491.2004.01332.x PMID: 15569129.
36. Karlsson HK, Hallsten K, Bjornholm M, Tsuchida H, Chibalin AV, Virtanen KA, et al. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes. 2005;54(5):1459-67. PMID: 15855334.
37. Viljanen AP, Virtanen KA, Jarvisalo MJ, Hallsten K, Parkkola R, Ronnemaa T, et al. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. The Journal of clinical endocrinology and metabolism. 2005;90(12):6523-8. doi: 10.1210/jc.2005-1073 PMID: 16189256.
38. De Fronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine. 1995;333(9):541-9. doi: 10.1056/NEJM199508313330902 PMID: 7623902.
39. Del Prato S, Erkelens DW, Leutenegger M. Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta diabetologica. 2003;40(1):20-7. doi: 10.1007/s005920300004 PMID: 12682825.
40. Damsbo P, Hermann LS, Vaag A, Hother-Nielsen O, Beck-Nielsen H. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin. Diabetes care. 1998;21(9):1489-94. PMID: 9727896.
41. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes care. 1991;14(4):342-4. PMID: 2060439.
42. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta diabetologica. 1998;35(1):34-40. PMID: 9625287
43. Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes care. 1998;21(7):1058-61. PMID: 9653595.
44. Derosa G, Maffioli P, Ferrari I, Fogari E, D'Angelo A, Palumbo I, et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. European journal of pharmacology. 2011;651(1-3):240-50. doi: 10.1016/j.ejphar.2010.11.015 PMID: 21118681.
45. Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Kohler C, Wildbrett J, et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes, obesity and metabolism. 2003;5(1):38-44. PMID: 12542723.
46. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes care. 1991;14(8):732-7. PMID: 1954810
47. Hanefeld M, Haffner SM, Menschikowski M, Koehler C, Temelkova-Kurktschiev T, Wildbrett J, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes research and clinical practice. 2002;55(3):221-7. PMID: 11850098.
48. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetic medicine: ajournal of the British Diabetic Association. 1993;10(2):134-8. PMID: 8458189.
49. Hwu CM, Ho LT, Fuh MM, Siu SC, Sutanegara D, Piliang S, et al. Acarbose improves glycemiccontrol in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. Diabetes research and clinical practice. 2003;60(2):111-8. PMID: 12706319.
50. Josse RG, Chiasson JL, Ryan EA, Lau DC, Ross SA, Yale JF, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes research and clinical practice. 2003;59(1):37-42. PMID: 12482640.
51. Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, et al. Treating Postprandial Hyperglycemia Does Not Appear to Delay Progression of Early Type 2 Diabetes The Early Diabetes Intervention Program. Diabetes care. 2006;29(9):2095-101. PMID: 16936159
52. Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes care. 2000;23(8):1162-7. PMID: 10937515.
53. Rosenbaum P, Peres RB, Zanella MT, Ferreira SR. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Brazilian journal of medical and biological research. 2002;35(8):877-84. PMID: 12185379.
54. Scott R, Lintott CJ, Zimmet P, Campbell L, Bowen K, Welborn T. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diabetes research and clinical practice. 1999;43(3):179-85. PMID: 10369427.
55. Wolever T, Chiasson J, Josse R, Hunt J, Palmason C, Rodger N, et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. International Journal of Obesity and Related Metabolic Disorders. 1997;21(9).
56. Wu GT, Han YQ, Yu YC, Teng XH, Zhang JC, Qu FJ. Effect of acarbose on insulin resistance in type 2 diabetic patients. Chinese Journal of New Drugs and Clinical Remedies. 2003;22(9):535-8.
57. Buchanan DR, Collier A, Rodrigues E, Millar AM, Gray RS, Clarke BF. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes. European journal of clinical pharmacology. 1988;34(1):51-3. PMID: 3282895.
58. Amador-Licona N, Guizar-Mendoza J, Vargas E, Sanchez-Camargo G, Zamora-Mata L. The shortterm effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Archives of medical research. 2000;31(6):571-5. PMID: 11257323.
59. Chien HH, Chang CT, Chu NF, Hsieh SH, Huang YY, Lee IT, et al. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. Journal of the Chinese Medical Association. 2007;70(11):473-80. doi: 10.1016/S1726-4901 (08) 70044-3 PMID: 18063500.
60. Ramachandran A, Snehalatha C, Salini J, Vijay V. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes-a study in Indians. Journal of the Association of Physicians of India. 2004;52:459-63. PMID: 15645955
61. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosedType 2 diabetes. Diabetic medicine: ajournal of the British Diabetic Association. 2005;22(8):980-5. doi: 10.1111/j.1464-5491.2005.01656.x PMID: 16026361.
62. Chen HH, Yang RJ. Clinical observation of glipizide and metformin release tablets in the treatment of type 2 diabetes. Medical Innovation of China. 2012;9(14):55-6.
63. Jia ZH, Liu KF. Clinical analysis of glipizide and metformin in the treatment of type 2 diabetes. Chinese remedies and clinics. 2005;5(8):627-8.
64. Ling ZM. Clinical observation of glimepiride in the treatment of type 2 diabetes. Journal of clinical medicine in practice. 2003;7(6):574-5.
65. Liu YT, Hu B, Jian L, Li JW, Huang L. Influence of metformin on level of serum vaspin in T2DM patients. Chinese Journal of Diabetes. 2013;21(8):705-8.
66. Tang JZ, Mao JP, Yang ZF, Zhou ZG, Tang WL, Feng Q. Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus. Journal of Central South University (Medical Sciences). 2004;29(6):631-4. PMID: 16114544
67. Wang H. Observation of therapeutic effect of metformin on 68 onset obese T2DM patients. Journal of medical forum. 2011;32(23):156-7.
68. Xu Y, Sun BR, Ye MH, Ding YJ. Clinical observation of type 2 diabetes treatment with glimepiride. Journal of practical medical techniques 2006;13(9):1503-4.
69. Yao J, Lu GZ, Yang JK, Liu JJ, Zhu LY, Lv XF, et al. Multicenter, randomized, double-masked, doublemimic active-controlled clinical trial of glipizide/metformin hydrochloride tablets for patients with type 2 diabetes. The Chinese Journal of Clinical Pharmacology. 2008;24(5):387-91.
70. Yao L, Lv XF, Ji X, Zhang JL. Clinical study on efficacy and security of fixed-dose glipizide/metformin on type 2 diabetes mellitus (DM). Chinese Journal of Clinical Pharmacology and Therapeutics. 2010;15(7):803-8.
71. Zhang HP. A Clinical trial on observing the availability and safety of fixed-dose metformin/glipizide on type 2 diabetes. Jilin province: JiLin university. 2009:1-27.
72. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clinical therapeutics. 2003;25(3):890-903. PMID: 12852706
73. Xuan WT, Liu YH, Huang JP, Ye JR, Liu CL. Comparison of gumepiride and metformin on plasminogen activator inhibitor-1 in coronary heart disease (CHD) patients accompanied with type 2 diabetes mellitus (T2DM). Modern Hospital. 2012;12(7):44-5.
74. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic medicine: ajournal of the British Diabetic Association. 2001;18(10):828-34. PMID: 11678974.
75. Formoso G, De Filippis EA, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes/metabolism research and reviews. 2008;24(3):231-7. doi: 10.1002/dmrr. 794 PMID: 17966969.
76. Ning J, Tang WL, Zhou ZG, Feng Q, Liu YH, Zhou WD. Effect of glimepiride and metformine on insulin resistance in type 2 diabetics. China Journal of Modern Medicine. 2006;16(14):2224-6.
77. Tessier D, Maheux P, Khalil A, Fulop T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism: clinical and experimental. 1999;48(7):897-903. PMID: 10421233.
78. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes care. 2004;27(1):41-6. PMID: 14693964.
79. Hasegawa G, Kajiyama S, Tanaka T, Imai S, Kozai H, Fujinami A, et al. Thealpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes. Clinicachimicaacta; international journal of clinical chemistry. 2008;390(1-2):110-4. doi: 10.1016/j.cca.2008.01.005 PMID: 18230353.
80. Hu HJ, Lei L, Zhao ZQ. Comparison of the effect of glimepiride and acarbose on newly diagnosed type 2 diabetic patients. Journal of Guiyang College of Traditional Chinese Medicine. 2012;34(5):70-1.
81. Li JR, Dai JD. Application of acarbose combined with glipizide in treatment of 30 elderly patients with type 2 diabetes. Herald of Medicine. 2007;26(5):510-1.
82. Li L. Comparison of the hypoglycemic effect of glimepiride and acarbose. China Practical Medicine. 2008;3(23):134-5.
83. Rosenthal JH, Mauersberger H. Effects on blood pressure of the oglucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical drug investigation. 2002;22(10):695-701.
84. Salman S, Salman F, Satman I, Yilmaz Y, Ozer E, Sengul A, et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin. 2001;16(4):296-306. doi: 10.1185/030079901750120231 PMID: WOS:000167506000008.
85. Van de Laar FA, Lucassen PLBJ, Kemp J, van de Lisdonk EH, van Weel C, Rutten G E H M. Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial. Diabetes research and clinical practice. 2004;63(1):57-65. doi: 10.1016/j. diabres.2003.08.006 PMID: WOS:000188218400007.
86. Wang YL, Bo ZS, Ma YL, Ma DZ. Clinical study of acarbose in the treatment of elderly patients with type 2 diabetes. Practical geriatrics. 1999;13(6):317-8.
87. Wang YH, Cui RZ. Clinical observation of diabetes 2 treatment with glimepiride. Journal of practical medical techniques. 2007;14(11):1429.
88. Yang H, Wu XR, Lin HZ. Cost-effectiveness analysis of 3 different drugs in the treatment of type 2 diabetes mellitus. China medical herald. 2010;7(27):116-8.
89. Donegan S, Williamson P, Gamble C, Tudur-Smith C. Indirect comparisons: a review of reporting and methodological quality. PloSone. 2010;5(11):e11054. doi: 10.1371/journal.pone.0011054 PMID: 21085712; PubMed Central PMCID: PMC2978085.
90. Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, Eastwood AJ, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. British Medical Journal. 2011;343.
91. Li Y, Tong Y, Zhang Y, Huang L, Wu T, Tong N. Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis. International journal of clinical practice. 2014;68(11):1318-32. doi: 10.1111/ijcp. 12467 PMID: 24853116.
92. Hu FB. Dietary pattern analysis: a new direction in nutritional epidemiology. Curr Opin Lipidol. 2002;13(1):3-9. doi: 10.1097/00041433-200202000-00002 PMID: WOS:000174080900002.
93. Song FJ, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials. 2000;21(5):488-97. doi: 10.1016/S0197-2456 (00) 00055-6 PMID: WOS:000089699200006.
94. Black N. Why we need observational studies to evaluate the effectiveness of health care. British Medical Journal. 1996;312(7040):1215-8. PMID: WOS:A1996UL05800026.
95. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2012;35(6):1364-79. doi: 10.2337/dc12-0413 PMID: 22517736
96. Group UPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet. 1998;352(9131):854-65. PMID: 9742977
97. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo Segura M, Roquéi Figuls M, Moher D. Metformin monotherapy for type 2 diabetes mellitus (Review). The Cochrane Library. 2013; (4:): 1-144.
98. Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014;17(2):157-73. doi: 10.1016/j.jval.2014.01.004 PMID: 24636374.